In contrast to this study, we observed an increased sensitivity towards venetoclax using S100A9-siRNA in venetoclax-sensitive (KG-1a and MOLM-13) and venetoclax-insensitive (OCI-AML3 and THP-1) AML cell lines, and in primary patient samples. This evidence concerns the gene GDI1 and acute myeloid leukemia.